AMD

Prevention should be at the forefront of the discussion.

The FDA determined it could not approve the BLA during this review cycle due to several CMC issues, open observations from pre-approval manufacturing inspections, and a lack of substantial evidence.

Clinicians may have difficulty in making a diagnosis.

According to Regeneron, the approval was based on data in the PULSAR and PHOTON trials, in which the drug demonstrated clinically equivalent vision gains to aflibercept Injection 2 mg that were maintained with fewer injections.

According to Regeneron, visual gains and safety of aflibercept 8 mg remained consistent with the established profile of aflibercept 2 mg injection.

The investigators explored the effects of the following covariates on development of AMD: sex, ethnicity, smoking history, fluoxetine use, obesity, diabetes mellitus, and hypertension.

Arshad M. Khanani, MD, MA, FASRS, sat down with Optometry Times to discuss the recent FDA approval of avacincaptad pegol intravitreal solution for treatment of geographic atrophy.

Paul Hahn, MD, PhD, shared insights on research comparing the relative efficacy of pegcetacoplan versus avacincaptad pegol in patients with geographic atrophy presented at the 2023 ASRS annual meeting.

Opthea’s lead biologic drug candidate OPT-302, which is under investigation for the treatment of wet AMD, received nonproprietary drug name sozinibercept, which is a critical step in the FDA approval process.

Jay M. Haynie, OD, FAAO, FORS, caught up with Peg Achenbach, OD, FAAO, while at the 2023 Victoria Conference to share highlights from his presentation on staying current with the AMD landscape.

While these injections are the standard treatment for this patient population, the investigators found a subgroup of patients who had severe visual loss between 2 consecutive intravitreal injections.

Researchers investigated the relationship between visual functioning measured using the National Eye Institute 25-Item Visual Function Questionnaire (VFQ-25) and mortality in patients with various stages of AMD.

A recently completed non-human primate study of VGX-0111 demonstrated good tolerability, provided strong transgene expression in the targeted region of the retina, and increased production of the lipids whose decline is associated with macular degeneration.

Mohammad Rafieetary, OD, FAAO, shares brief highlights from his 2023 AOA presentation, "AMD updates: Staying current with its landscape," which he co-presented with Jay Haynie, OD, FAAO.

Over the past decade the progress in retinal disease treatments has exploded with increased numbers of approved pharmaceutical compounds, resulting in more options for treating retinal disease with intravitreal agents and more are in the pipeline.

Jeffry Gerson, OD, FAAO, who presented a poster on the Light Site 3 clinical study at the AOA online e-poster event, discusses a promising new treatment for patients with AMD.

The day helps to bring focus and awareness to risk factors for early vision loss associated with smoking.

The iPredict AI Eye Screening System will provide a fully automated age-related macular degeneration (AMD) screening report in less than 60 seconds.

The two companies have announced an exclusive agreement for Polifarma to commercialize AVT06, the proposed biosimilar to Eylea, in Turkey.

Acceptance is based on two phase 3 studies that demonstrated early and sustained vision improvement, meeting primary endpoint of non-inferiority compared to aflibercept.

Alvin Liu, MD, sat down with Sheryl Stevenson, Group Editorial Director, Ophthalmology Times®, to discuss his presentation on deep learning and 3D OCT at the ASCRS annual meeting in San Diego.

Efavirenz boosts cholesterol turnover in retina, brain.

Tina Mac Donald, OD, shares highlights from her presentation on living with an untreatable eye disease, which she presented during the 2023 Controversies in Modern Eye Care meeting.

Leo Semes, OD, shares highlights from his presentation on early detection of AMD, which he presented during the 17th annual Controversies in Modern Eye Care.

David Liao, MD, shares highlights from his discussion on evolving treatment strategies for neovascular AMD and DME, during the 17th annual Controversies in Modern Eye Care meeting.